{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:53:06Z","timestamp":1776966786216,"version":"3.51.4"},"reference-count":25,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pfizer, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.2217\/fon-2022-1018","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T10:55:59Z","timestamp":1683111359000},"page":"775-787","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma"],"prefix":"10.1080","volume":"19","author":[{"given":"Patrick","family":"Hlavacek","sequence":"first","affiliation":[{"name":"Pfizer, Inc.,\rNew York,\rNY10017,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Schepart","sequence":"additional","affiliation":[{"name":"Pfizer, Inc.,\rNew York,\rNY10017,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison R","family":"Silverstein","sequence":"additional","affiliation":[{"name":"Inovalon Insights,\rBowie,\rMD20716, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5056-4897","authenticated-orcid":false,"given":"Allison A","family":"Petrilla","sequence":"additional","affiliation":[{"name":"Inovalon Insights,\rBowie,\rMD20716, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Johnson","sequence":"additional","affiliation":[{"name":"Inovalon Insights,\rBowie,\rMD20716, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Avalere Health,\rWashington, DC20005, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0023"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_3_5_5_1","unstructured":"Key statistics about multiple myeloma. www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.html (6 February 2023)."},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405016"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2020.S008"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2698"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1"},{"key":"e_1_3_5_12_1","unstructured":"BLENREP Prescribing information. GlaxoSmithKlineUnited States (2020)."},{"key":"e_1_3_5_13_1","unstructured":"SARCLISA\u00ae Prescribing information. Sanofi-Aventis U.S. LLCUnited States (2020)."},{"key":"e_1_3_5_14_1","unstructured":"ABECMA\u00ae Prescribing information. Bristol-Myers SquibbUnited States (2021)."},{"key":"e_1_3_5_15_1","unstructured":"CARVYKTI\u2122 Prescribing information. Janssen BiotechUnited States (2022)."},{"key":"e_1_3_5_16_1","unstructured":"U.S. Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. (16 January 2023). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2013.33.e302"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.01.005"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0669-4"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-021-00175-z"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1003"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.09.013"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3446-y"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01159-9"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00335"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-1018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:31Z","timestamp":1719125071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-1018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.2217\/fon-2022-1018"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-1018","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}